Maxim Group Initiates Coverage on Zevra Therapeutics (NASDAQ:ZVRA)

Equities research analysts at Maxim Group started coverage on shares of Zevra Therapeutics (NASDAQ:ZVRA – Get Rating) in a research note issued on Friday, The Fly reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s target price would indicate a potential upside of 150.00% from the company’s current price.

Zevra Therapeutics Stock Up 1.9 %

Shares of ZVRA stock opened at $4.80 on Friday. Zevra Therapeutics has a 52-week low of $4.00 and a 52-week high of $6.92. The company has a quick ratio of 7.93, a current ratio of 7.93 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $165.79 million, a price-to-earnings ratio of -4.00 and a beta of 2.15.

Insiders Place Their Bets

In other news, CEO Richard W. Pascoe acquired 10,000 shares of Zevra Therapeutics stock in a transaction on Thursday, March 9th. The stock was acquired at an average cost of $4.20 per share, with a total value of $42,000.00. Following the transaction, the chief executive officer now owns 29,973 shares of the company’s stock, valued at approximately $125,886.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Matthew R. Plooster bought 11,000 shares of the company’s stock in a transaction on Thursday, March 9th. The shares were purchased at an average cost of $4.20 per share, for a total transaction of $46,200.00. Following the completion of the purchase, the director now directly owns 18,500 shares in the company, valued at $77,700. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Richard W. Pascoe bought 10,000 shares of the company’s stock in a transaction on Thursday, March 9th. The stock was bought at an average price of $4.20 per share, for a total transaction of $42,000.00. Following the completion of the purchase, the chief executive officer now owns 29,973 shares of the company’s stock, valued at $125,886.60. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 25,925 shares of company stock valued at $109,547. Corporate insiders own 1.10% of the company’s stock.

Zevra Therapeutics Company Profile

(Get Rating)

Zevra Therapeutics, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.